shukrapharmaceuticals.comCrawled Nov 9, 2026
Strengthen clinical capabilities with Shukra Pharmaceuticals Ltd (BSE: 524632 | NSE: SHUKRAPHAR) advanced surgical solutions — smart operating room integration, electrosurgical units, and laparoscopic systems.
The page covers Shukra Pharmaceuticals Ltd’s advanced cardiovascular technologies, including cardiac imaging, electrophysiology, coronary interventions, and patient monitoring.
Empowering diabetes care with Shukra Pharmaceuticals Ltd (BSE: 524632 | NSE: SHUKRAPHAR) integrated continuous glucose monitoring (CGM) systems, automated insulin delivery, and smart diabetes management solutions.
High-precision diagnostic solutions from Shukra Pharmaceuticals Ltd (BSE: 524632 | NSE: SHUKRAPHAR) — automated clinical chemistry, immunoassay analyzers, hematology, and point-of-care testing (POCT).
Shukra Pharmaceuticals Ltd offers career opportunities in pharmaceuticals and medical robotics.
Shukra MedTech introduces engineering teams and biomedical specialists focused on surgical robotics and medical device development.
Shukra Pharmaceuticals Ltd highlights executive leaders and manufacturing heads overseeing pharmaceutical formulations, quality assurance, and global healthcare supply.
Shukra Labs features scientists, lab directors, and R&D experts specializing in analytical testing, quality assurance, and diagnostics.
The page describes Shukra Pharmaceuticals Ltd, an Indian pharmaceutical and MedTech company, including its history since 1993, leadership, and core values under Chairman & Managing Director Mr. Dakshesh Shah.
Discover Shukra Pharmaceuticals Ltd (BSE: 524632 | NSE: SHUKRAPHAR) international presence and global export network delivering high-quality pharmaceutical formulations and medical technologies worldwide.
Access financial results, annual reports, corporate announcements, shareholding patterns, and investor contacts for Shukra Pharmaceuticals Ltd, registered and listed on BSE (Scrip Code: 524632) and NSE (Symbol: SHUKRAPHAR).
The page provides contact details for Shukra Pharmaceuticals Ltd, including its corporate headquarters in Bodakdev, Ahmedabad, Gujarat, and investor relations, corporate, and sales teams.
Shukra Pharmaceuticals Ltd (BSE: 524632 | NSE: SHUKRAPHAR) is a registered Indian pharmaceutical and MedTech company delivering advanced healthcare solutions across pharmaceuticals, medical devices, surgical robotics, diagnostics, and global markets.
The Privacy Policy explains how Shukra Pharmaceuticals Ltd collects, protects, and handles data in compliance with privacy regulations.
The page outlines the Terms of Use for Shukra Pharmaceuticals Ltd, covering website services, intellectual property, and medical information disclaimers.
Shukra Pharma’s market value jumps from ₹7 crore in 2021 to nearly ₹1,837 crore as the company expands into medical technology. The small-cap healthcare firm enters segments like medical imaging, robotics, and diabetes devices, driving investor interest. Growth reflects a shift toward high-margin medtech products amid rising demand in India’s healthcare sector.
Mar 2026Business TodayNews article
Shukra Pharmaceuticals receives a Letter of Intent (LoI) from YEIDA for a **Rs 600-crore facility** in Greater Noida, focusing on **advanced surgical robotics** and **BNCT (Boron Neutron Capture Therapy)** production. The project will create **over 900 direct jobs** and partner with **Borns Medical Robotics Inc.** to introduce high-precision surgical robotics in India, aiming to improve affordability and accessibility across the region.
Feb 2026The Economic TimesNews article
Shukra Pharmaceuticals receives a letter of intent from the Yamuna Expressway Industrial Development Authority (YEIDA) for a land parcel to establish a Rs 600 crore manufacturing facility. The company plans to utilize the site for scaling production operations. The approval marks a key step in expanding Shukra Pharma’s industrial capacity in the region.
Feb 2026The WeekNews article
Shukra Pharmaceuticals Limited secures exclusive rights to distribute and manage Wockhardt Ltd.’s anti-infective products. The agreement grants Shukra the role of agent, distributor, and manager for Wockhardt’s evolved pharmaceutical portfolio in a specified market. Wockhardt, a global pharmaceutical company, delegates these responsibilities to expand its reach through Shukra’s distribution network.
Sep 2025indiapharmaoutlook.comNews article